NHS study confirms higher reporting rate for OGT’s CytoSure v3 array

Wednesday 22 July 2020
Applications:
Product types:
Scientist_loads_sample_large

Oxford, UK – 22 July 2020. In a recent, prominent, npj Genomic Medicine paper, Oxford Gene Technology’s (OGT - A Sysmex Group Company) CytoSure™ Constitutional v3 array design has been shown to significantly improve reporting rate and been proven as a powerful tool for detection of small pathogenic intragenic deletions and duplications in developmental disorder (DD) research. The paper, titled Exon-focused targeted oligonucleotide microarray design increases detection of clinically relevant variants across multiple NHS genomic centres was led by a consortium of NHS genomic medicine centres in the UK and compared the enhanced exon-level gene coverage of the v3 array to a conventional array design.

The study consisted of a large cohort of 27,756 patient samples. These were investigated with either OGT’s exon targeted CytoSure Constitutional v3 array, based on up-to-date content from the Deciphering Developmental Disorders (DDD) study and ClinGen (Clinical Genome Resource), or a conventional array design based on content from the ISCA (International Standards for Cytogenomic Arrays) consortium with a large number of backbone probes and gene coverage based on an earlier version DD/ID databases.

The results demonstrated that the v3 array had a significant increase in reporting rate of 4.49%, confirming that the enhanced, targeted exon-level coverage design enables more reportable copy number variations (CNVs) to be identified than with traditional arrays. The authors of the paper believe the findings of the research will help to enable clinical researchers to assess optimal testing pathways when integrating genomics into labs. They also note that targeted arrays offer robust CNV detection and provide a stable, proven platform with both simple data analysis and minimal demands on bioinformatics.

Lead author Jana Jezkova from the All Wales Medical Genomics Service, Cardiff and Vale University Health Board, Cardiff noted “In this paper, we evaluated the performance of a targeted oligonucleotide array CGH with enhanced exon-level coverage of genes associated with developmental disorders (CytoSure Constitutional v3). The study was conducted across multiple genomic medicine centres in a state-funded routine National Health Service (NHS) setting. Our results show that this array design leads to a significant improvement in reporting rate and provides a powerful tool for detection of small pathogenic intragenic deletions and duplications in the clinical setting. Although next generation sequencing is increasingly being used to simultaneously identify copy number changes along with single nucleotide variants, at this time, targeted arrays offer a robust method of copy number detection and offer a stable, proven platform with simple data analysis and minimal demands on bioinformatics capacity. Given the drive towards national genomic-medicine initiatives to provide consistent and equitable care for patients, we believe that the findings presented in our paper will appeal to publicly funded laboratories as well as genetics teams and referring clinicians. Our findings will allow the readers to assess optimal analysis pathways when integrating genomics into healthcare.”

OGT’s CytoSure Constitutional v3 arrays feature the most up-to-date and relevant ID/DD content with probes for up to 502 highly-targeted genes identified by ClinGen and the DDD project—enabling detection of single exon aberrations. OGT’s array design delivers high probe density across the exons and introns of important genes that enables improved detection of small (<500bp) deletions and duplications that may otherwise be missed or require manual calling on other older array designs.

Emma Shipstone, Executive VP Marketing, commented “We’re delighted with this publication as it validates what we’ve always known about the performance of our CytoSure Constitutional v3 array and the quality of the data—it’s great to see that crystallised in this research. OGT is renowned for our unparalleled design capabilities and our commitment to the constitutional cytogenetics space—our arrays are widely trusted and regarded as the best on the market. It’s wonderful to see this research confirm our superior design compared to more conventional arrays and that this importantly enables scientists to identify more relevant aberrations underlying developmental delay. This design concept is something that we have translated in to our recently launched CytoSure NGS assay, which, as Jana notes, provides users the ability to assess the appropriate analytical pathway for their laboratory.”

The npj Genomic Medicine paper can be accessed at: https://rdcu.be/b5KWZ.

 

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856800 ; F: +44 (0) 1865 848684

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

 

Editor’s notes

About Oxford Gene Technology

Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease. OGT was acquired by Sysmex Corporation (Sysmex), a Japanese in vitro diagnostic company in June 2017. The acquisition of OGT expands Sysmex’s life science business and reinforces its initiatives towards personalised medicine.

For more information on the Company, please visit our website at www.ogt.com

CytoSure™, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. Cytocell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.